key: cord-0252213-9vo6jbiu authors: Khan, Nabab title: mTOR: A possible therapeutic target against SARS-CoV-2 infection date: 2021 journal: Arch Stem Cell Ther DOI: nan sha: 50b667362e0bf102b019900e65f15c67a090e8ba doc_id: 252213 cord_uid: 9vo6jbiu nan rapalog (everolimus) [39, 48] , which target the mTOR-signaling pathway. Recently, rapalog has been shown a protective role in small samples of COVID-19 aged patients [47] [48] [49] [50] . Rapalog, an analog of rapamycin, is commonly used as an immunosuppressant [51] . However, it exerts immunostimulatory effects, for example, enhancing T-cell response in microbes' infection and behaving as an immunoadjuvant in vaccination [52] . Hence, a placebo study should be conducted to explore and screen existed rapamycin like synthetic and natural compounds against SARS-CoV-2 infection and COVID-19 in vitro and in vivo conditions [43] . Table 1 contains the list of clinical trials of natural and synthetic mTOR inhibitors against COVID-19. Here briefly concludes that the mTOR sensor might be a potential therapeutic target to suppress SARS-CoV-2 infection and its pathogenesis, COVID-19. Hence, mTOR inhibitors, synthetic and mainly naturally available compounds, should be screened to determine their potency to suppress SARS-CoV-2 infection and COVID-19. A multibasic cleavage site in the spike protein of SARS-CoV-2 is essential for infection of human lung cells SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor A molecular pore spans the double membrane of the coronavirus replication organelle Role of Endolysosomes in Severe Acute Respiratory Syndrome Coronavirus-2 Infection and Coronavirus Disease 2019 Pathogenesis: Implications for Potential Treatments Ultrastructure and origin of membrane vesicles associated with the severe acute respiratory syndrome coronavirus replication complex Possible role of adenosine in COVID-19 pathogenesis and therapeutic opportunities Targeting the endocytic pathway and autophagy process as a novel therapeutic strategy in COVID-19 Endolysosomes are the principal intracellular sites of acid hydrolase activity Possible protective role of 17β-estradiol against COVID-19 Involvement of organelles and inter-organellar signaling in the pathogenesis of HIV-1 associated neurocognitive disorder and Alzheimer's disease. Brain Research Age-related endolysosome dysfunction in the rat urothelium Disorders of lysosomal acidification-The emerging role of v-ATPase in aging and neurodegenerative disease Regulation of V-ATPase assembly in nutrient sensing and function of V-ATPases in breast cancer metastasis BK channels regulate extracellular Tat-mediated HIV-1 LTR transactivation. Scientific Reports Two-pore channels regulate Tat endolysosome escape and Tat-mediated HIV-1 LTR transactivation SLC38A9 is a component of the lysosomal amino acid sensing machinery that controls mTORC1 Ragulator and SLC38A9 activate the Rag GTPases through noncanonical GEF mechanisms Lysosomal amino acid transporter SLC38A9 signals arginine sufficiency to mTORC1 Lysosomal pH plays a key role in regulation of mTOR activity in osteoclasts mTORC1 senses lysosomal amino acids through an inside-out mechanism that requires the vacuolar H+-ATPase mTOR regulates lysosomal ATPsensitive two-pore Na+ channels to adapt to metabolic state mTOR signaling in cardiometabolic disease, cancer, and aging mTOR signaling in growth control and disease Pathogens menTORing macrophages and dendritic cells: Manipulation of mTOR and cellular Metabolism to promote immune escape Regulation of immune responses by mTOR. Annual Review of Immunology mTOR signaling in growth, metabolism, and disease mTOR as regulator of lifespan, aging, and cellular senescence: a mini-review Comprehending a killer: the Akt/mTOR signaling pathways are temporally high-jacked by the highly pathogenic 1918 influenza virus. EBioMedicine Modulation of mTORC1 Signaling Pathway by HIV-1. Cells Rapamycinmediated mTOR inhibition uncouples HIV-1 latency reversal from cytokine-associated toxicity. The Journal of Clinical Investigation Antiviral potential of ERK/MAPK and PI3K/AKT/mTOR signaling modulation for Middle East respiratory syndrome coronavirus infection as identified by temporal kinome analysis Inhaled biguanides and mTOR inhibition for influenza and coronavirus Dysregulation in Akt/mTOR/HIF-1 signaling identified by proteo-transcriptomics of SARS-CoV-2 infected cells. Emerging Microbes & Infections The global phosphorylation landscape of SARS-CoV-2 infection Antiviral drug screen of kinase inhibitors identifies cellular signaling pathways critical for SARS-CoV-2 replication. Available at SSRN 3682004 Effective inhibition of MERS-CoV infection by resveratrol. BMC Infectious Diseases The mechanistic target of rapamycin (mTOR): novel considerations as an antiviral treatment Immunoregulation with mTOR inhibitors to prevent COVID-19 severity: A novel intervention strategy beyond vaccines and specific antiviral medicines An open question: is it rational to inhibit the mTor-dependent pathway as COVID-19 therapy? mTOR inhibition in COVID-19: A commentary and review of efficacy in RNA viruses Inhibition of PI3K/Akt/mTOR signaling by natural products. Anti-Cancer Agents in Medicinal Chemistry Resveratrol downregulates PI3K/Akt/mTOR signaling pathways in human U251 glioma cells Possible Therapeutic Use of Natural Compounds Against COVID-19 Metformin and COVID-19: From cellular mechanisms to reduced mortality Observational study of metformin and risk of mortality in patients hospitalized with Covid-19 Rapamycin as a potential repurpose drug candidate for the treatment of COVID-19 Targeting T-cell senescence and cytokine storm with rapamycin to prevent severe progression in COVID-19 Geroprotective and senoremediative strategies to reduce the comorbidity, infection rates, severity, and lethality in gerophilic and gerolavic infections The potential of rapalogs to enhance resilience against SARS-CoV-2 infection and reduce the severity of COVID-19. The Lancet Healthy Longevity Repurposing drugs, ongoing vaccine and new therapeutic development initiatives against COVID-19 Selective effects of mTOR inhibitor sirolimus on naïve and CMV-Specific T cells extending its applicable range beyond immunosuppression Paradoxical aspects of rapamycin immunobiology in transplantation Author manuscript; available in PMC This work was partly supported by NIH grant RO1 (MH119000). The mTOR sensor is exploited by SARS-CoV-2 for replication and survives in cells. However, mTOR inhibitors could suppress SARS-CoV-2 replication and COVID-19 by inducing autophagy, restricting the synthesis of viral proteins and inflammation. Khan Page 6Arch Stem Cell Ther. Author manuscript; available in PMC 2021 June 24.